VICTORION-1 PREVENT
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
- Stage
- followup
- Medicine
- Inclisiran
- Population
- ASCVD
- Phase
- III
- First Patient In
- 12 September 2023
- Last Patient In
- 26 July 2024
- Last Patient Last Visit
- 30 September 2028
National Lead
prof. dr. E.S.G. Stroes
Cardioloog
Study Director
